Secchi O, Franchi A, Lunello A. Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”. AboutOpen [Internet]. 2023 Jun. 5 [cited 2024 Nov. 21];10(1):82-6. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2600